Haemonetics Corp risk profile
45 Elevated one input has moved against it
Measured 21 October 2026 from HAE's filed statements. Recomputed nightly.
45 (Elevated), driven by Concentration at 71, over 6 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 36 | Normal | Volatile | One-year price volatility — 51.6% |
| Operating pressure | Reads cost_of_revenue, operating_expense, operating_income and revenue. No reading is stored for this company. | |||
| Cash conversion | 9 | Contained | Easing | Capital spending against operating cash — 0.11x |
| Leverage and coverage | 36 | Normal | Worsening | Net debt to EBITDA — 3.65x |
| Competitive position | 62 | Stretched | Stable | Revenue-growth gap against peers — -17.1 percentage points |
| Concentration | 71 | Stretched | Stable | Geographic concentration — 5,682 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for Haemonetics Corp